Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPA-201 T Cell Therapy for PD-(L)1 Resistant Solid Tumors
NCT05144698Phase 2Recruiting
- Sponsor
- Rapa Therapeutics
- Start
- Aug 2021
- Primary completion
- Jan 2026
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
A Phase 2 trial of rapa-201 in solid tumor, Malignant Melanoma (MM), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), head and neck cancer (HNC), sponsored by Rapa Therapeutics. Started Aug 2021; status: recruiting.
02
Drugs
rapa-201
03
Conditions
solid tumorMalignant Melanoma (MM)small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT05144698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144698.